Heidelberg Pharma Investor Relations Material
Latest events
Status Update
Heidelberg Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Heidelberg Pharma AG
Access all reports
Heidelberg Pharma is a biopharmaceutical company that focuses on oncology and antibody targeted amanitin conjugates (ATAC). Their innovations are based on cell immunotherapy and the drug amanitin conjugates (ATAC). The tumor cells are attacked by immune cells, which recognize the amanitin antigen as a foreign body. This way the treatment causes no mutilation of healthy tissue.
Key slides for Heidelberg Pharma AG
Q4 2024
Heidelberg Pharma AG
Q4 2024
Heidelberg Pharma AG
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
HPHA
Country
🇩🇪 Germany